← All companies

Gilead Sciences (GILD)

Hold Current rating · 4 reports

Coverage summary

Aardvark Labs Capital Research has covered Gilead Sciences (GILD) since February 11, 2026. The company is in the Healthcare sector. This page lists 4 reports: 4 earnings recaps.

The latest is the Q3 2026 Earnings Recap, published November 1, 2026. That report moved the rating from Outperform to Hold. The rating has changed twice since coverage began.

Translations: 3 in Chinese.

Rating history

  1. First rating: Hold Q4 2025 Earnings Recap
  2. Hold → Outperform Q1 2026 Earnings Recap
  3. Outperform → Hold Q3 2026 Earnings Recap

All GILD reports

2026-11-01

Hold Recap: Q3 2026

The Best Quarter Since 2015 Meets a 19x Multiple and a $1.5B Biktarvy Price Cut: Downgrading to Hold
2026-08-09

Outperform Recap: Q2 2026

PrEP Clears $1B a Quarter and Persistency Finally Has a Number, But the Revenue Raise Never Reaches EPS
2026-05-08

Outperform Recap: Q1 2026

Gilead Beats, Raises, and Falls Anyway on $11.5B of M&A Charges: Upgrading to Outperform
2026-02-11

Hold Recap: Q4 2025

Gilead Beats and Prints a Record High, But the 2026 Guide Lands Light: Initiating at Hold